TABLE 2.
Correlation of CDK6 expression of clinical characteristics in non-APL AML patients.
| Characteristics | Low (n = 78) | High (n = 79) | P-value |
| Male/Female | 42/36 | 43/36 | 0.941 |
| Median age, years (range) | 62 (31-88) | 56 (18-82) | 0.006 |
| Median WBC (109/l, range) | 25.9 (1.2-137.2) | 14.3 (0.6-297) | 0.281 |
| Median BM blasts (range) | 71 (30-98) | 72 (32-100) | 0.209 |
| Median PB blasts (range) | 17 (0-90) | 54 (0-98) | 0.000 |
| FAB | |||
| M0 | 1 | 15 | 0.000 |
| M1 | 14 | 30 | 0.005 |
| M2 | 12 | 26 | 0.01 |
| M4 | 32 | 2 | 0.000 |
| M5 | 16 | 2 | 0.000 |
| M6 | 2 | 0 | 0.471 |
| M7 | 0 | 3 | 0.248 |
| No data | 1 | 1 | |
| Cytogenetics | |||
| normal | 40 | 37 | 0.377 |
| inv(16) | 9 | 1 | 0.021 |
| -7/7q- | 1 | 4 | 0.371 |
| t(8;21) | 0 | 6 | 0.039 |
| del(5) | 0 | 1 | 1 |
| 11q23 | 4 | 0 | 0.125 |
| +8 | 3 | 5 | 0.731 |
| complex | 10 | 14 | 0.394 |
| Other | 9 | 8 | 0.776 |
| No data | 1 | 2 | |
| Risk cytogenetic | |||
| Good | 9 | 8 | 0.776 |
| Intermediate | 51 | 49 | 0.662 |
| Poor | 18 | 22 | 0.493 |
| Mutation | |||
| FLT3 | 23 | 21 | 0.685 |
| NPM1 | 29 | 19 | 0.074 |
| DNMT3A | 22 | 21 | 0.820 |
| IDH2 | 7 | 10 | 0.458 |
| TET2 | 6 | 9 | 0.430 |
| RUNX1 | 7 | 9 | 0.617 |
| TP53 | 6 | 9 | 0.430 |
| NRAS | 6 | 5 | 0.738 |
| CEBPA | 2 | 11 | 0.01 |
| WT1 | 3 | 7 | 0.337 |
| KRAS | 5 | 2 | 0.429 |
| Treatment | |||
| CR | 24 | 32 | 0.203 |